DAOL Securities Thailand released an analysis today estimating that The Clinic Clinic Vejchakam, or KLINIQ, is likely to post standout results in the third quarter of 2026 and could set a new record, with net profit expected at around 125 to 130 million baht. The growth is driven by revenue expanding along with the opening of 10 new branches, together with same-store sales growth that continues at a double-digit pace, reflecting still-strong demand for services. Meanwhile, the ratio of selling and administrative expenses to revenue is trending lower thanks to more efficient cost management, which should support profitability in the second half of the year. For the full year 2026, DAOL Securities estimates KLINIQ's net profit at 476 million baht, up 31% from the previous year, and sees room for an upward revision if profit trends in the remainder of the year come in better than expected. DAOL Securities therefore maintains its Buy recommendation on KLINIQ with a target price of 35 baht, citing a positive view on profit growth, branch expansion, and improved cost-control efficiency.
The Klinique Med Clinic PCLDAOL Securities maintains Buy with 35 baht target, forecasting record Q3 net profit of 125-130 million baht and 2026 profit up 31%.
